HCV-infection | CMAC

HCV-infection

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism

Objective. To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism. Materials and Methods. An open-label, non-randomized, observational study to assess efficacy and safety of DAA in patients (n = 143) with chronic hepatitis C (CHC) and liver cirrhosis and UGT1A1*28 polymorphism was performed. A total of 139 patients with chronic HCV infection were included in the efficacy analysis (absence of HCV RNA in blood by PCR) by the rate of sustained virologic response at week 12 (SVR12).

Clinical case of difficult differential diagnosis between liver cirrhosis and hepatocellular carcinoma associated with HCV infection in a patient with prolonged alcohol exposure

This paper presents a clinical case of large focal liver mass in a 55-year old patient with HCV-associated liver cirrhosis and prolonged high-dose alcohol exposure. Given the inconsistency between clinical data and ultrasound examination results as …